Gilgamesh Pharmaceuticals
American pharmaceutical company
From Wikipedia, the free encyclopedia
Gilgamesh Pharmaceuticals is a pharmaceutical company that is developing psychedelic and related drugs as medicines.[2][3][4] It is a "discovery stage" company and is focused on developing new chemical entities.[1]
| |
| Industry | Pharmaceutical; Psychedelic medicine |
|---|---|
| Founded | 2019[1] |
| Headquarters | , United States  |
| Website | www |
Its drug candidates include the ketamine-related NMDA receptor antagonist blixeprodil (GM-1020; (R)-4-fluorodeschloroketamine or (R)-4-FDCK), the dimethyltryptamine (DMT)-related serotonergic psychedelic bretisilocin (GM-2505; 5-fluoro-N-methyl-N-ethyltryptamine or 5F-MET), the noribogaine-related κ-opioid receptor agonist GM-3009, and the non-hallucinogenic psychoplastogen GM-5022.[2][3][5][6][4] Another potential candidate is GM-2040, a putatively non-hallucinogenic serotonin 5-HT2A receptor agonist.[7]
The company was co-founded by Jonathan Sporn, Jeff Witkin, Dalibor Sames, Andrew Kruegel, and Mike Cunningham.[1] Cunningham is a research scientist at Gilgamesh.[8] Sames, Kruegel, and Cunningham have worked together at Sames's lab at Columbia University.[1]
In May 2024, AbbVie made an optional deal with Gilgamesh Pharmaceuticals to pay $65 million upright for rights to novel non-hallucinogenic psychoplastogens.[1][9][10] It also agreed to pay up to $1.95 billion for a series of psychoplastogens.[1][9][10] In August 2025, AbbVie acquired bretisilocin from Gilgamesh Pharmaceuticals in a deal worth up to $1.2 billion.[11]
